Last reviewed · How we verify
Gemcitabine/ clindamycin
This combination pairs gemcitabine, a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells, with clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis.
This combination pairs gemcitabine, a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells, with clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis. Used for Unknown indication under Phase 3 evaluation by Prisma Health-Upstate.
At a glance
| Generic name | Gemcitabine/ clindamycin |
|---|---|
| Sponsor | Prisma Health-Upstate |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and apoptosis in cancer cells. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The rationale for combining these agents in a Phase 3 trial is unclear from available literature, though such combinations may target both malignant and microbial components in certain infections or explore immunomodulatory synergy.
Approved indications
- Unknown indication under Phase 3 evaluation by Prisma Health-Upstate
Common side effects
- Myelosuppression (gemcitabine)
- Nausea and vomiting (gemcitabine)
- Diarrhea (clindamycin)
- Pseudomembranous colitis (clindamycin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |